SCHEMBL30145146

SCHEMBL30145146

COc1cc(Cl)c(-c2cnn3c2CN(Cc2nc4nc(Cl)ccc4[nH]2)CC3)cc1OC

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MARS2 Q96GW9 7/20 0.47
▸ ABCB1 P08183 3/20 0.38
▸ DRD4 P21917 4/20 0.36
▸ DRD2 P14416 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ BLM P54132 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ LMNA P02545 1/20 0.32
▸ PRMT5 O14744 1/20 0.32
▸ WDR77 Q9BQA1 1/20 0.32
▸ CACNA1G O43497 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20595888 1.00 MARS2 (0.47) MARS2ABCB1DRD4DRD2KDM4E
SCHEMBL30145087 0.89 MARS2 (0.45) MARS2ABCB1DRD4ALDH1A1MAPT
SCHEMBL20596106 0.89 MARS2 (0.45) MARS2ABCB1DRD4ALDH1A1MAPT
SCHEMBL20596033 0.80 MARS2 (0.46) MARS2DRD4KDM4EALDH1A1MAPT
SCHEMBL30145270 0.80 MARS2 (0.46) MARS2DRD4KDM4EALDH1A1MAPT
SCHEMBL20595909 0.74 MARS2 (0.52) MARS2ABCB1DRD4DRD2KDM4E
SCHEMBL30145285 0.74 MARS2 (0.52) MARS2ABCB1DRD4DRD2KDM4E
SCHEMBL20595969 0.68 MARS2 (0.43) MARS2DRD4DRD2
SCHEMBL30145209 0.68 MARS2 (0.43) MARS2DRD4DRD2
SCHEMBL20595993 0.67 MARS2 (0.52) MARS2DRD4DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 MARS2 12/4885ABCB1 2032/4885DRD4 4438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback